Air pollution modelling using a graphics processing unit with CUDA

The Graphics Processing Unit (GPU) is a powerful tool for parallel computing. In the past years the performance and capabilities of GPUs have increased, and the Compute Unified Device Architecture (CUDA) - a parallel computing architecture - has been developed by NVIDIA to utilize this performance in general purpose computations. Here we show for the first time a possible application of GPU for environmental studies serving as a basement for decision making strategies. A stochastic Lagrangian particle model has been developed on CUDA to estimate the transport and the transformation of the radionuclides from a single point source during an accidental release. Our results show that parallel implementation achieves typical acceleration values in the order of 80-120 times compared to CPU using a single-threaded implementation on a 2.33 GHz desktop computer. Only very small differences have been found between the results obtained from GPU and CPU simulations, which are comparable with the effect of stochastic transport phenomena in atmosphere. The relatively high speedup with no additional costs to maintain this parallel architecture could result in a wide usage of GPU for diversified environmental applications in the near future.Comment: 5 figure

Probability of the emergence of helical precipitation patterns in the wake of reaction-diffusion fronts

Helical and helicoidal precipitation patterns emerging in the wake of reaction-diffusion fronts are studied. In our experiments, these chiral structures arise with well-defined probabilities P_H controlled by conditions such as e.g., the initial concentration of the reagents. We develop a model which describes the observed experimental trends. The results suggest that P_H is determined by a delicate interplay among the time and length scales related to the front and to the unstable precipitation modes and, furthermore, the noise amplitude also plays a quantifiable role.Comment: 7 pages, 5 composite figure

Schizotypal Perceptual Aberrations of Time: Correlation between Score, Behavior and Brain Activity

A fundamental trait of the human self is its continuum experience of space and time. Perceptual aberrations of this spatial and temporal continuity is a major characteristic of schizophrenia spectrum disturbances – including schizophrenia, schizotypal personality disorder and schizotypy. We have previously found the classical Perceptual Aberration Scale (PAS) scores, related to body and space, to be positively correlated with both behavior and temporo-parietal activation in healthy participants performing a task involving self-projection in space. However, not much is known about the relationship between temporal perceptual aberration, behavior and brain activity. To this aim, we composed a temporal Perceptual Aberration Scale (tPAS) similar to the traditional PAS. Testing on 170 participants suggested similar performance for PAS and tPAS. We then correlated tPAS and PAS scores to participants' performance and neural activity in a task of self-projection in time. tPAS scores correlated positively with reaction times across task conditions, as did PAS scores. Evoked potential mapping and electrical neuroimaging showed self-projection in time to recruit a network of brain regions at the left anterior temporal cortex, right temporo-parietal junction, and occipito-temporal cortex, and duration of activation in this network positively correlated with tPAS and PAS scores. These data demonstrate that schizotypal perceptual aberrations of both time and space, as reflected by tPAS and PAS scores, are positively correlated with performance and brain activation during self-projection in time in healthy individuals along the schizophrenia spectrum

472 Issues in Information Systems

ABSTRAC

Functional compounds of einkorn and emmer genotypes

Three einkorn and two emmer genotypes were analysed for concentration of microelements (Fe, Zn and Se) and lipid soluble antioxidants (α-tocopherol, α-tocotrienol and β-carotene). A diversity was observed in micronutrient content, but most of the genotypes have significantly higher trace element and antioxidant contents than the control wheat variety. The emmer genotypes contain lower Fe and β-carotene concentration than einkorn genotypes. The einkorn genotypes have significant higher antioxidant content than the wheat control. On average einkorn has more than three times more β-carotene than the wheat variety. Our results are useful for species/variety choice in functional food production not only for organic but also for conventional farmers, who have/want to operate under low input conditions, especially in Central Europe

Self in time: imagined self-location influences neural activity related to mental time travel

Conscious awareness of the self as continuous through time is attributed to the human ability to remember the past and to predict the future, a cogitation that has been called "mental time travel" (MTT). MTT allows one to re-experience one's own past by subjectively "locating" the self to a previously experienced place and time, or to pre-experience an event by locating the self into the future. Here, we used a novel behavioral paradigm in combination with evoked potential mapping and electrical neuroimaging, revealing that MTT is composed of two different cognitive processes: absolute MTT, which is the location of the self to different points in time (past, present, or future), and relative MTT, which is the location of one's self with respect to the experienced event (relative past and relative future). These processes recruit a network of brain areas in distinct time periods including the occipitotemporal, temporoparietal, and anteromedial temporal cortices. Our findings suggest that in addition to autobiographical memory processes, the cognitive mechanisms of MTT also involve mental imagery and self-location, and that relative MTT, but not absolute MTT, is more strongly directed to future prediction than to past recollection

HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.

BackgroundHuman epidermal growth factor receptor 2 (HER2)-positive breast cancer is a particularly aggressive form of the disease, and ultimately progresses in patients with metastases on standard therapies. Anthracyclines, such as doxorubicin, are an effective treatment for HER2-positive breast cancer, particularly when administered in combination with trastuzumab - however, doxorubicin-related cardiotoxicity has limited its use. Many patients are therefore never treated with anthracyclines, even upon disease progression, despite the potential for benefit. MM-302 is a novel, HER2-targeted antibody-liposomal doxorubicin conjugate that specifically targets HER2-overexpressing cells. Preclinical and Phase 1 data suggest that MM-302, as a monotherapy or in combination with trastuzumab, could be effective for managing previously treated, anthracycline-naïve, HER2-positive breast cancer, without the cardiotoxicity observed with free doxorubicin formulations.Methods/designHERMIONE is an open-label, multicenter, randomized (1:1) Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice (gemcitabine, capecitabine, or vinorelbine) plus trastuzumab planned to enroll 250 anthracycline-naïve patients with locally advanced/metastatic HER2-positive breast cancer. Key inclusion criteria are: previous treatment with trastuzumab (with or without pertuzumab) in any setting; refractory or intolerant to pertuzumab (refractory to pertuzumab defined as progression in the locally advanced or metastatic setting, or disease recurrence during or within 12 months of completing pertuzumab-containing neoadjuvant and/or adjuvant therapy); and disease progression on, or intolerant to, ado-trastuzumab emtansine for locally advanced or metastatic disease. The trial is currently being conducted at sites in the USA, Canada, and Western Europe. Treatment will be administered in 21-day cycles, and will be continued until disease progression or unacceptable toxicity. The primary endpoint is independently assessed progression-free survival (PFS). Tumor response will be assessed every 6 weeks, and defined according to RECIST v1.1. Secondary endpoints include investigator-assessed PFS, overall survival (OS), OS rates at 6 months and 1 year, objective response rates, safety and tolerability, quality of life, and the pharmacokinetic profile of MM-302 plus trastuzumab.DiscussionThe HERMIONE study will evaluate the efficacy and safety of MM-302 plus trastuzumab in patients with refractory HER2-positive advanced/metastatic breast cancer for whom there are no standard of care therapies with a proven survival advantage.Trial registrationClinicaltrials.gov identifier: NCT02213744 . Registration date: 06AUG2014